Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from InhaleRx Limited ( (AU:IRX) ) is now available.
InhaleRx Limited held its Annual General Meeting on May 29, 2025, where twelve resolutions were voted on by members. The meeting’s outcomes included the approval of various resolutions such as the re-election of directors and the issuance of performance rights to directors, while some resolutions, like the approval of incentive securities for certain directors, were not carried. These decisions reflect the company’s strategic focus on governance and incentivization, impacting its operational and market positioning.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical stage biotechnology company focused on developing rapid onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company aims to pursue U.S. FDA approval through rapid and cost-effective regulatory pathways, targeting significant economic opportunities with products like IRX-211 for Breakthrough Cancer Pain and IRX-616a for Panic Disorder.
Average Trading Volume: 223,612
Technical Sentiment Signal: Hold
Current Market Cap: A$5.76M
For detailed information about IRX stock, go to TipRanks’ Stock Analysis page.